These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


707 related items for PubMed ID: 16820790

  • 1. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.
    Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, Derksen RH, Berden JH, Dutch Working Party on Systemic Lupus Erythematosus.
    Kidney Int; 2006 Aug; 70(4):732-42. PubMed ID: 16820790
    [Abstract] [Full Text] [Related]

  • 2. Treatment of proliferative lupus nephritis: a changing landscape.
    Adu D.
    Kidney Int; 2006 Aug; 70(4):616-8. PubMed ID: 16900218
    [Abstract] [Full Text] [Related]

  • 3. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis.
    Arends S, Grootscholten C, Derksen RH, Berger SP, de Sévaux RG, Voskuyl AE, Bijl M, Berden JH, Dutch Working Party on systemic lupus erythematosus.
    Ann Rheum Dis; 2012 Jun; 71(6):966-73. PubMed ID: 22128082
    [Abstract] [Full Text] [Related]

  • 4. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C, Bajema IM, Florquin S, Steenbergen EJ, Peutz-Kootstra CJ, Goldschmeding R, Bijl M, Hagen EC, Van Houwelingen HC, Derksen RH, Berden JH, Dutch Working Party on Systemic Lupus Erythematosus.
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [Abstract] [Full Text] [Related]

  • 5. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
    Contreras G, Tozman E, Nahar N, Metz D.
    Lupus; 2005 Mar; 14 Suppl 1():s33-8. PubMed ID: 15803929
    [Abstract] [Full Text] [Related]

  • 6. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
    Moroni G, Doria A, Mosca M, Alberighi OD, Ferraccioli G, Todesco S, Manno C, Altieri P, Ferrara R, Greco S, Ponticelli C.
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):925-32. PubMed ID: 17699309
    [Abstract] [Full Text] [Related]

  • 7. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.
    Mejía-Vilet JM, Arreola-Guerra JM, Córdova-Sánchez BM, Morales-Buenrostro LE, Uribe-Uribe NO, Correa-Rotter R.
    J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566
    [Abstract] [Full Text] [Related]

  • 8. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
    Chan TM, Tse KC, Tang CS, Mok MY, Li FK, Hong Kong Nephrology Study Group.
    J Am Soc Nephrol; 2005 Apr; 16(4):1076-84. PubMed ID: 15728784
    [Abstract] [Full Text] [Related]

  • 9. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
    Arends S, Berden JH, Grootscholten C, Derksen RH, Berger SP, de Sévaux RG, Voskuyl AE, Bijl M, Dutch Working Party on SLE.
    Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
    [Abstract] [Full Text] [Related]

  • 10. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.
    Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R, MAINTAIN Nephritis Trial Group.
    Ann Rheum Dis; 2010 Dec; 69(12):2083-9. PubMed ID: 20833738
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [Abstract] [Full Text] [Related]

  • 12. Immunosuppressive therapy in lupus nephritis.
    D'Cruz D, Cuadrado MJ, Mujic F, Tungekar MF, Taub N, Lloyd M, Khamashta MA, Hughes GR.
    Clin Exp Rheumatol; 1997 Aug; 15(3):275-82. PubMed ID: 9177922
    [Abstract] [Full Text] [Related]

  • 13. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.
    Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC.
    Am J Kidney Dis; 2001 Aug; 38(2):256-64. PubMed ID: 11479150
    [Abstract] [Full Text] [Related]

  • 14. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.
    Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, Chen J, Lin H, Liu F, He Y, He Y, Miao L, Chen N, Li Y, Gu Y, Shi W, Hu W, Liu Z, Bao H, Zeng C, Zhou M.
    Ann Intern Med; 2015 Jan 06; 162(1):18-26. PubMed ID: 25383558
    [Abstract] [Full Text] [Related]

  • 15. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.
    Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT.
    Ann Intern Med; 2001 Aug 21; 135(4):248-57. PubMed ID: 11511139
    [Abstract] [Full Text] [Related]

  • 16. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts.
    Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, Lazaro E, Iza A, Couzi L, Saenz R, Richez C, Porta S, Blanco P.
    Autoimmun Rev; 2017 Aug 21; 16(8):826-832. PubMed ID: 28564619
    [Abstract] [Full Text] [Related]

  • 17. Sequential therapies for proliferative lupus nephritis.
    Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D.
    N Engl J Med; 2004 Mar 04; 350(10):971-80. PubMed ID: 14999109
    [Abstract] [Full Text] [Related]

  • 18. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, Kumar V, Kohli HS, Sakhuja V, Jha V, Gupta KL.
    Kidney Int; 2016 Jan 04; 89(1):235-42. PubMed ID: 26489028
    [Abstract] [Full Text] [Related]

  • 19. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial.
    Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD.
    Ann Intern Med; 1996 Oct 01; 125(7):549-57. PubMed ID: 8815753
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
    Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN.
    N Engl J Med; 2000 Oct 19; 343(16):1156-62. PubMed ID: 11036121
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 36.